high blood pressure primary aldosteronism
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Newly diagnosed hypertensive patients in general practice
Exclusion criteria
Exclusion criteria: Use of antihypertensive medication Heart failure class II, III or IV (according to the New York Heart Association) Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1: Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in Dutch general practice Part 2: Difference in cardiorenovascular damage in patients with versus without PA, based on a composite of the following parameters: - Left ventricular mass index in g/m2 - Intima-media thickness of carotid artery in mm - Pulse wave velocity in m/s - Central aortic blood pressure in mmHg - Flow-mediated dilation in % - Albuminuria in mg albumin per mmol creatinin Part 3: Difference in reduction of daytime systolic ABPM in patients with normokalemic PA versus patients with essential hypertension in a standardized treatment regimen during conventional antihypertensive therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 2: to observe differences in • Serum potassium • Low density lipoprotein • Total cholesterol to high density lipoprotein ratio Part 3: to observe differences in • Reduction of daytime systolic ABPM in patients with PA versus patients with essential hypertension in a standardized treatment regimen during spironolactone (or eplerenone) • Serum potassium response using conventional antihypertensive medication • Adverse effects using conventional antihypertensive medication • Serum potassium response using spironolactone (or eplerenone) • Adverse effects using spironolactone (or eplerenone) | — |
Countries
Netherlands
Outcome results
None listed